Hulskof schreef op 23 december 2020 12:19:
Ali Mortazavi, CEO van E-Therapeutics dat zich nu ook een RNAi firma mag noemen, twittert de volgende serie:
1/ Lot of talk about how mRNA is ‘plug and play’ and you can make a new sequence in 6 weeks. Firstly, each new sequence should theoretically be a NME. mRNA/siRNA sequences aren’t quite that simple and can have off target effects and behave differently with chemical modifications.
2/ Even if the 6 weeks was true, there is then the question of manufacturing and distribution. There is then the question (I don’t have the answer) of how many times can you stimulate immunity, especially considering the unknowns of LNP tox and novelty of the mRNA. #COVID19
3/ Any DNA/RNA drug based on Watson Crick base pairing can be designed in silico and synthesised very fast. That’s the huge advantage over small molecules for example. But look at $ALNY AAT programme for what ‘any old sequence’ can do.
4/ Back in the good old days of oncogenes, the fantasy in RNAi was that you could play chess with cancer when it mutates. You would simply make a new sequence every time the cancer mutated. Sadly, cancer cells are a lot more devious than expected.
5/ For example, GalNAc conjugates use the ASGPR receptor in hepatocytes extremely efficiently for siRNA delivery. In HCC... the receptor is basically deleted.
Impliceert hij hier oa dat RNAi tekortschiet als aanpak tegen kanker?